Creative Medical Technology Holdings Inc.'s Immcelz (CELZ-101) has been awarded orphan drug designation by the FDA. Immcelz is aimed at preventing allograft rejection in patients undergoing pancreatic islet cell transplantation.
It has been hypothesized that allogeneic, hypoimmune (HIP) iPSC-derived or donor-derived islet grafts could provide a new and safe therapeutic alternative for the treatment of type 1 diabetes mellitus (T1DM). Researchers from Sana Biotechnology Inc. and affiliated organizations have published preclinical data from studies further assessing this novel strategy in nonhuman primates (NHPs).
Kakao Healthcare Corp. launched an artificial intelligence (AI)-powered mobile application called PASTA on Feb. 1 for continuous glucose monitoring (CGM)-based diabetes care. PASTA pairs with two types of CGM sensors, either from Seoul-based I-sens Inc.’s Caresens Air or San Diego-based Dexcom Inc.’s G7 system.
A company focused on regulating immune response through nanoparticle technology, Cour Pharmaceuticals Development Co. Inc. has raised $105 million in a series A round to move its lead autoimmune disease products into phase IIa trials.
Encellin Inc. has announced the closing of a US$9.9 million financing round that will support the company’s development of its cell encapsulation platform with an initial focus on type 1 diabetes.
With hybrid closed-loop systems for automated insulin delivery increasingly being seen as life changing for people with diabetes, Vicentra BV has teamed up with Diabeloop SA and Dexcom Inc. to launch a system to help people with type 1 diabetes manage their condition.
The Swedish Medical Products Agency has authorized Uppsala University's clinical trial application to initiate an investigator-sponsored, first-in-human study of UP-421, an allogeneic, primary islet cell therapy engineered with Sana Biotechnology Inc.'s hypoimmune technology, in patients with type 1 diabetes.
The U.K. National Institute for Health and Care Excellence (NICE) has seen the nation’s spending numbers for diabetes, which is said to account for roughly 10% of healthcare spending in the U.K., and responded in a collaboration with the National Health Service (NHS).
Itolerance Inc. and Kadimastem Ltd. have submitted a meeting request to the FDA's INTERACT committee for ITOL-102, which is under development as a potential cure for type 1 diabetes without the need for chronic immunosuppression.
Sab Biotherapeutics Inc. has obtained human research ethics committee (HREC) approval in Australia to commence a first-in-human phase I trial investigating SAB-142 for type 1 diabetes.
